Abstract 1676P
Background
Breast cancer (BC) survivors face many problems regarding sex. A range of medical treatments targeted to breast cancer patients leave behind large side effects that can negatively influence their sex life and change their body image, their self-esteem and their confidence. Most Tunisian Breast cancer survivors are reluctant to discuss their sexual problems with their doctors. Thus, their troubled sex life remains hidden. The aim of our study was to identify those sexual difficulties and to address the problems our patients are facing.
Methods
Patients diagnosed and treated for BC at the medical oncology department with active sex life prior to diagnosis were asked to complete a questionnaire from January to March 2023. The survey’s aim is to highlight the underlying problems breast cancer survivors are confronting and to help them lead a healthy sex life. One hundred women participated in our study.
Results
The medium age for our patients was 52.24 years. In our population, 52% of the women underwent radical mastectomy. All of our patients underwent radiotherapy and 88% underwent chemotherapy. Before BC diagnosis, patients who rarely had sex represent 28% of the women, those who had sex once a week represent 52% and those who had sex on a regular basis (more than once a week) represented 20% of the population. After surgery, 72% of our patients reported rarely having sexual relationships (less than once a month). Only 16% of our patients reported having intercourse once a week. As for patients who maintained a regular sex life after surgery (more than once a week), they represent 12% of the population. This drop in the frequency of sexual relationship is linked to multiple causes: body dysmorphia and failure to accept body changes 76%, lower libido in 80%; less vaginal sensation in 64% and vaginal dryness in 84%. Dyspareunia was experienced by 60% compared 36% before surgery. None of the women sought medical consult. No medication nor lubrification was used by the patients to improve their symptoms.
Conclusions
Breast cancer survivors are reluctant to discuss their sexuality and the problems they are facing after surgery. Even though patients don’t ask for help, it is our duty as clinicians to identify the problems and help our patients to receive the adequate treatment and advice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1636P - Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Presenter: Renée Bultijnck
Session: Poster session 11
1637P - Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study
Presenter: Neeraj Agarwal
Session: Poster session 11
1638P - Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age
Presenter: Neal Shore
Session: Poster session 11
1639P - Self efficacy in people with prostate cancer in the UK: A large, digital survey
Presenter: Joe O'Sullivan
Session: Poster session 11
1640P - Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients
Presenter: Ziyun Wang
Session: Poster session 11
1641P - Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
Presenter: Christos Kyriakopoulos
Session: Poster session 11
1642P - Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis
Presenter: Charles Vauchier
Session: Poster session 11
1643P - Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC)
Presenter: Bicky Thapa
Session: Poster session 11
1644P - PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Lana Broer
Session: Poster session 11
1645P - Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients
Presenter: Marta Garcia De Herreros
Session: Poster session 11